Breaking News Bar

Business News and Information

Tauriga Sciences, Inc. Completes Payment for the Entirety of its Initial Production Run of its Black Currant Flavor Cannabigerol Infused Tauri-Gum

This Initial Production Run is Expected to Yield Approximately 8,500 Blister Packs – Concentration of Cannabigerol (“CBG”) has Been Increased to 15mg / Each Piece of Chewing Gum

 

NEW YORK, NY - (NewMediaWire) - June 12, 2020 - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with a proprietary line of functional “supplement” chewing gums (versions: infused with CBD, CBG, Vitamin C & Zinc) and edibles product(s) as well as two ongoing Biotechnology initiatives, today announced that it has completed payment for the entirety of its initial production run of its 2nd Cannabigerol (“CBG”) infused version of Tauri-Gum™ (Black Currant Flavor).  This initial production is expected to yield approximately 8,500 Blister Packs (850 Retail Boxes) and there have already been strong levels of customer interest expressed toward this newest Tauri-Gum™ product version.  The Black Currant Tauri-Gum™ product version is infused with 15mg of CBG/each piece of chewing gum: MSRP has been set @ $22.99 per Blister Pack. 

 

On May 26, 2020 the Company announced the arrival of its Peach-Lemon Tauri-Gum™ inventory (the Company’s 1st CBG infused product version) - at its E-Commerce fulfillment center.  Sales of Peach-Lemon flavor Tauri-Gum™ (10mg CBG/each piece of chewing gum) have been very strong.

 

ABOUT TAURIGA SCIENCES INC.

 

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum™ Flavor: Peach-Lemon).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com

 

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment).  On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

 

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

 

         

DISCLAIMER -- Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

 

Contact:

 

CONTACT INFORMATION

Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY  10022
Chief Executive Officer
Mr. Seth M. Shaw
Email:  sshaw@tauriga.com
cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw
Corp. 
Website:   www.tauriga.com

E-Commerce Website:  www.taurigum.com

 

 

 

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear